Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Paclitaxel | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, in vitro knockdown |
| Sample | breast cancer tissues, cell lines (MDA-MB-231 and MDA-MB-231p) |
| Expression Pattern | up-regulated |
| Function Description | Patients with an overall positive treatment response had higher let-7a and lower H19 levels. We also identified that the nonresponders had higher H19 expression levels. In addition, Pearson r correlation analyses indicated that let-7a expression was negatively associated with H19 expression. Patients with a risk score of >-0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity. These results may indicate that H19 regulates drug resistance by impairing apoptosis. |
| Pubmed ID | 29963109 |
| Year | 2018 |
| Title | Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |